In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...

Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...